nodes	percent_of_prediction	percent_of_DWPC	metapath
Fluvoxamine—CYP1A1—Thalidomide—leprosy	0.0677	0.0801	CbGbCtD
Fluvoxamine—CYP3A7—Rifampicin—leprosy	0.0525	0.062	CbGbCtD
Fluvoxamine—CYP3A7-CYP3A51P—Rifampicin—leprosy	0.0525	0.062	CbGbCtD
Fluvoxamine—CYP2E1—Thalidomide—leprosy	0.0523	0.0618	CbGbCtD
Fluvoxamine—CYP2E1—Rifampicin—leprosy	0.0507	0.0599	CbGbCtD
Fluvoxamine—CYP2B6—Rifampicin—leprosy	0.05	0.0591	CbGbCtD
Fluvoxamine—CYP3A7—Dapsone—leprosy	0.0433	0.0512	CbGbCtD
Fluvoxamine—CYP3A7-CYP3A51P—Dapsone—leprosy	0.0433	0.0512	CbGbCtD
Fluvoxamine—CYP2E1—Dapsone—leprosy	0.0418	0.0494	CbGbCtD
Fluvoxamine—CYP3A5—Thalidomide—leprosy	0.0407	0.0481	CbGbCtD
Fluvoxamine—CYP3A5—Rifampicin—leprosy	0.0394	0.0465	CbGbCtD
Fluvoxamine—CYP2C19—Thalidomide—leprosy	0.0328	0.0388	CbGbCtD
Fluvoxamine—CYP3A5—Dapsone—leprosy	0.0325	0.0384	CbGbCtD
Fluvoxamine—CYP2C19—Rifampicin—leprosy	0.0318	0.0375	CbGbCtD
Fluvoxamine—CYP1A2—Thalidomide—leprosy	0.0303	0.0358	CbGbCtD
Fluvoxamine—CYP1A2—Rifampicin—leprosy	0.0293	0.0346	CbGbCtD
Fluvoxamine—CYP2C9—Thalidomide—leprosy	0.0273	0.0322	CbGbCtD
Fluvoxamine—CYP2C9—Rifampicin—leprosy	0.0264	0.0312	CbGbCtD
Fluvoxamine—CYP2C19—Dapsone—leprosy	0.0262	0.031	CbGbCtD
Fluvoxamine—ABCB1—Rifampicin—leprosy	0.0256	0.0303	CbGbCtD
Fluvoxamine—CYP2C9—Dapsone—leprosy	0.0218	0.0258	CbGbCtD
Fluvoxamine—CYP3A4—Rifampicin—leprosy	0.0154	0.0181	CbGbCtD
Fluvoxamine—CYP3A4—Dapsone—leprosy	0.0127	0.015	CbGbCtD
Fluvoxamine—Ligament sprain—Dapsone—leprosy	0.00535	0.0348	CcSEcCtD
Fluvoxamine—Menopause—Thalidomide—leprosy	0.00305	0.0198	CcSEcCtD
Fluvoxamine—Hangover—Thalidomide—leprosy	0.00294	0.0191	CcSEcCtD
Fluvoxamine—Application site reaction—Dapsone—leprosy	0.00288	0.0187	CcSEcCtD
Fluvoxamine—Enuresis—Thalidomide—leprosy	0.00242	0.0157	CcSEcCtD
Fluvoxamine—Suicide attempt—Dapsone—leprosy	0.00238	0.0155	CcSEcCtD
Fluvoxamine—Lacrimal structural disorder—Thalidomide—leprosy	0.00236	0.0153	CcSEcCtD
Fluvoxamine—Pericarditis—Thalidomide—leprosy	0.0016	0.0104	CcSEcCtD
Fluvoxamine—Lacrimal disorder—Thalidomide—leprosy	0.00155	0.0101	CcSEcCtD
Fluvoxamine—Hyporeflexia—Thalidomide—leprosy	0.00152	0.0099	CcSEcCtD
Fluvoxamine—Parkinsonism—Thalidomide—leprosy	0.00152	0.0099	CcSEcCtD
Fluvoxamine—Hernia—Thalidomide—leprosy	0.00148	0.0096	CcSEcCtD
Fluvoxamine—Neck stiffness—Thalidomide—leprosy	0.00145	0.00945	CcSEcCtD
Fluvoxamine—Tongue discolouration—Thalidomide—leprosy	0.00143	0.00931	CcSEcCtD
Fluvoxamine—Peripheral vascular disorder—Thalidomide—leprosy	0.00141	0.00918	CcSEcCtD
Fluvoxamine—White blood cell count decreased—Thalidomide—leprosy	0.00139	0.00904	CcSEcCtD
Fluvoxamine—Lactic dehydrogenase activity increased—Thalidomide—leprosy	0.00135	0.00879	CcSEcCtD
Fluvoxamine—Nuchal rigidity—Thalidomide—leprosy	0.00133	0.00867	CcSEcCtD
Fluvoxamine—Hostility—Thalidomide—leprosy	0.00125	0.00813	CcSEcCtD
Fluvoxamine—Sexual dysfunction—Thalidomide—leprosy	0.00123	0.00803	CcSEcCtD
Fluvoxamine—Suicide attempt—Thalidomide—leprosy	0.00122	0.00793	CcSEcCtD
Fluvoxamine—Inappropriate antidiuretic hormone secretion—Thalidomide—leprosy	0.00119	0.00774	CcSEcCtD
Fluvoxamine—Blood lactate dehydrogenase increased—Thalidomide—leprosy	0.00119	0.00774	CcSEcCtD
Fluvoxamine—Enlargement abdomen—Thalidomide—leprosy	0.00115	0.00748	CcSEcCtD
Fluvoxamine—Toothache—Thalidomide—leprosy	0.00114	0.0074	CcSEcCtD
Fluvoxamine—Psoriasis—Thalidomide—leprosy	0.0011	0.00716	CcSEcCtD
Fluvoxamine—Myasthenia—Thalidomide—leprosy	0.0011	0.00716	CcSEcCtD
Fluvoxamine—Hypothyroidism—Thalidomide—leprosy	0.00108	0.00701	CcSEcCtD
Fluvoxamine—Embolism—Thalidomide—leprosy	0.00108	0.00701	CcSEcCtD
Fluvoxamine—Tooth disorder—Thalidomide—leprosy	0.00107	0.00694	CcSEcCtD
Fluvoxamine—Galactorrhoea—Thalidomide—leprosy	0.00107	0.00694	CcSEcCtD
Fluvoxamine—Menstrual disorder—Thalidomide—leprosy	0.00102	0.0066	CcSEcCtD
Fluvoxamine—Seborrhoeic dermatitis—Thalidomide—leprosy	0.00102	0.0066	CcSEcCtD
Fluvoxamine—Intestinal obstruction—Thalidomide—leprosy	0.00102	0.0066	CcSEcCtD
Fluvoxamine—Neuralgia—Thalidomide—leprosy	0.000996	0.00648	CcSEcCtD
Fluvoxamine—Cyanosis—Thalidomide—leprosy	0.000978	0.00636	CcSEcCtD
Fluvoxamine—Interstitial lung disease—Thalidomide—leprosy	0.000978	0.00636	CcSEcCtD
Fluvoxamine—Metrorrhagia—Thalidomide—leprosy	0.000969	0.0063	CcSEcCtD
Fluvoxamine—Hyperlipidaemia—Thalidomide—leprosy	0.00096	0.00624	CcSEcCtD
Fluvoxamine—Psychotic disorder—Dapsone—leprosy	0.000959	0.00623	CcSEcCtD
Fluvoxamine—Stupor—Thalidomide—leprosy	0.000927	0.00603	CcSEcCtD
Fluvoxamine—Amblyopia—Thalidomide—leprosy	0.000896	0.00583	CcSEcCtD
Fluvoxamine—Hyperaesthesia—Thalidomide—leprosy	0.000882	0.00573	CcSEcCtD
Fluvoxamine—Muscular weakness—Dapsone—leprosy	0.000866	0.00563	CcSEcCtD
Fluvoxamine—Tingling sensation—Thalidomide—leprosy	0.000861	0.0056	CcSEcCtD
Fluvoxamine—Influenza—Dapsone—leprosy	0.000848	0.00551	CcSEcCtD
Fluvoxamine—Endocrine disorder—Thalidomide—leprosy	0.000835	0.00543	CcSEcCtD
Fluvoxamine—Pancreatitis—Dapsone—leprosy	0.000832	0.00541	CcSEcCtD
Fluvoxamine—Acne—Thalidomide—leprosy	0.000823	0.00535	CcSEcCtD
Fluvoxamine—Apnoea—Thalidomide—leprosy	0.000817	0.00531	CcSEcCtD
Fluvoxamine—Amenorrhoea—Thalidomide—leprosy	0.000788	0.00512	CcSEcCtD
Fluvoxamine—Accidental injury—Thalidomide—leprosy	0.000782	0.00509	CcSEcCtD
Fluvoxamine—Photosensitivity reaction—Dapsone—leprosy	0.000774	0.00503	CcSEcCtD
Fluvoxamine—Musculoskeletal stiffness—Thalidomide—leprosy	0.000772	0.00502	CcSEcCtD
Fluvoxamine—Viral infection—Thalidomide—leprosy	0.000766	0.00498	CcSEcCtD
Fluvoxamine—Skin discolouration—Thalidomide—leprosy	0.000766	0.00498	CcSEcCtD
Fluvoxamine—Bone disorder—Thalidomide—leprosy	0.000766	0.00498	CcSEcCtD
Fluvoxamine—Arthropathy—Thalidomide—leprosy	0.000761	0.00495	CcSEcCtD
Fluvoxamine—Thinking abnormal—Thalidomide—leprosy	0.000756	0.00492	CcSEcCtD
Fluvoxamine—Herpes simplex—Thalidomide—leprosy	0.000751	0.00488	CcSEcCtD
Fluvoxamine—Oliguria—Thalidomide—leprosy	0.000751	0.00488	CcSEcCtD
Fluvoxamine—Drug interaction—Thalidomide—leprosy	0.000746	0.00485	CcSEcCtD
Fluvoxamine—Neuropathy peripheral—Dapsone—leprosy	0.000741	0.00482	CcSEcCtD
Fluvoxamine—Dyskinesia—Thalidomide—leprosy	0.000737	0.00479	CcSEcCtD
Fluvoxamine—Leukocytosis—Thalidomide—leprosy	0.000737	0.00479	CcSEcCtD
Fluvoxamine—Hypercholesterolaemia—Thalidomide—leprosy	0.000732	0.00476	CcSEcCtD
Fluvoxamine—Bone pain—Thalidomide—leprosy	0.000723	0.0047	CcSEcCtD
Fluvoxamine—Atrioventricular block—Thalidomide—leprosy	0.000714	0.00464	CcSEcCtD
Fluvoxamine—Sinusitis—Dapsone—leprosy	0.00071	0.00461	CcSEcCtD
Fluvoxamine—Gait disturbance—Thalidomide—leprosy	0.000709	0.00461	CcSEcCtD
Fluvoxamine—Coordination abnormal—Thalidomide—leprosy	0.000705	0.00458	CcSEcCtD
Fluvoxamine—Neck pain—Thalidomide—leprosy	0.000701	0.00455	CcSEcCtD
Fluvoxamine—Eructation—Thalidomide—leprosy	0.00068	0.00442	CcSEcCtD
Fluvoxamine—Pharyngitis—Dapsone—leprosy	0.000674	0.00438	CcSEcCtD
Fluvoxamine—Depressed level of consciousness—Thalidomide—leprosy	0.000668	0.00435	CcSEcCtD
Fluvoxamine—Colitis—Thalidomide—leprosy	0.000665	0.00432	CcSEcCtD
Fluvoxamine—Neuropathy—Thalidomide—leprosy	0.00065	0.00422	CcSEcCtD
Fluvoxamine—Aplastic anaemia—Thalidomide—leprosy	0.00065	0.00422	CcSEcCtD
Fluvoxamine—Dry eye—Thalidomide—leprosy	0.000639	0.00416	CcSEcCtD
Fluvoxamine—Cramps of lower extremities—Thalidomide—leprosy	0.000636	0.00413	CcSEcCtD
Fluvoxamine—Tinnitus—Dapsone—leprosy	0.000633	0.00412	CcSEcCtD
Fluvoxamine—Oesophagitis—Thalidomide—leprosy	0.000633	0.00411	CcSEcCtD
Fluvoxamine—Rash maculo-papular—Thalidomide—leprosy	0.000629	0.00409	CcSEcCtD
Fluvoxamine—Hypertonia—Thalidomide—leprosy	0.000607	0.00394	CcSEcCtD
Fluvoxamine—Hyperkinesia—Thalidomide—leprosy	0.000604	0.00392	CcSEcCtD
Fluvoxamine—Mental disability—Thalidomide—leprosy	0.000601	0.0039	CcSEcCtD
Fluvoxamine—Euphoric mood—Thalidomide—leprosy	0.000595	0.00387	CcSEcCtD
Fluvoxamine—Lymphadenopathy—Thalidomide—leprosy	0.000589	0.00383	CcSEcCtD
Fluvoxamine—Diabetes mellitus—Thalidomide—leprosy	0.000578	0.00376	CcSEcCtD
Fluvoxamine—Photosensitivity—Thalidomide—leprosy	0.000572	0.00372	CcSEcCtD
Fluvoxamine—Gastroenteritis—Thalidomide—leprosy	0.000567	0.00369	CcSEcCtD
Fluvoxamine—Vascular purpura—Thalidomide—leprosy	0.000562	0.00365	CcSEcCtD
Fluvoxamine—Deafness—Thalidomide—leprosy	0.000562	0.00365	CcSEcCtD
Fluvoxamine—Eczema—Thalidomide—leprosy	0.000559	0.00363	CcSEcCtD
Fluvoxamine—Vision blurred—Dapsone—leprosy	0.000557	0.00362	CcSEcCtD
Fluvoxamine—Eye pain—Thalidomide—leprosy	0.000557	0.00362	CcSEcCtD
Fluvoxamine—Injury—Thalidomide—leprosy	0.000547	0.00355	CcSEcCtD
Fluvoxamine—Renal failure acute—Thalidomide—leprosy	0.000544	0.00354	CcSEcCtD
Fluvoxamine—Libido decreased—Thalidomide—leprosy	0.000542	0.00352	CcSEcCtD
Fluvoxamine—Increased appetite—Thalidomide—leprosy	0.000535	0.00348	CcSEcCtD
Fluvoxamine—Amnesia—Thalidomide—leprosy	0.000535	0.00348	CcSEcCtD
Fluvoxamine—Dermatitis exfoliative—Thalidomide—leprosy	0.000533	0.00346	CcSEcCtD
Fluvoxamine—Vertigo—Dapsone—leprosy	0.000531	0.00345	CcSEcCtD
Fluvoxamine—Visual disturbance—Thalidomide—leprosy	0.00053	0.00345	CcSEcCtD
Fluvoxamine—Dermatitis bullous—Thalidomide—leprosy	0.000526	0.00342	CcSEcCtD
Fluvoxamine—Purpura—Thalidomide—leprosy	0.000521	0.00339	CcSEcCtD
Fluvoxamine—Arthritis—Thalidomide—leprosy	0.000517	0.00336	CcSEcCtD
Fluvoxamine—Cough—Dapsone—leprosy	0.000516	0.00335	CcSEcCtD
Fluvoxamine—Hypoglycaemia—Thalidomide—leprosy	0.000515	0.00335	CcSEcCtD
Fluvoxamine—Cardiac failure—Thalidomide—leprosy	0.000515	0.00335	CcSEcCtD
Fluvoxamine—Lethargy—Thalidomide—leprosy	0.000513	0.00333	CcSEcCtD
Fluvoxamine—Cerebrovascular accident—Thalidomide—leprosy	0.000513	0.00333	CcSEcCtD
Fluvoxamine—Hyponatraemia—Thalidomide—leprosy	0.000505	0.00328	CcSEcCtD
Fluvoxamine—Osteoarthritis—Thalidomide—leprosy	0.000502	0.00327	CcSEcCtD
Fluvoxamine—Gastrointestinal haemorrhage—Thalidomide—leprosy	0.000502	0.00327	CcSEcCtD
Fluvoxamine—Diplopia—Thalidomide—leprosy	0.000502	0.00327	CcSEcCtD
Fluvoxamine—Disturbance in sexual arousal—Thalidomide—leprosy	0.000499	0.00324	CcSEcCtD
Fluvoxamine—Migraine—Thalidomide—leprosy	0.000495	0.00322	CcSEcCtD
Fluvoxamine—Affect lability—Thalidomide—leprosy	0.000495	0.00322	CcSEcCtD
Fluvoxamine—Psychotic disorder—Thalidomide—leprosy	0.000491	0.00319	CcSEcCtD
Fluvoxamine—Face oedema—Thalidomide—leprosy	0.000485	0.00315	CcSEcCtD
Fluvoxamine—Cardiac arrest—Thalidomide—leprosy	0.000478	0.00311	CcSEcCtD
Fluvoxamine—Mood swings—Thalidomide—leprosy	0.000476	0.00309	CcSEcCtD
Fluvoxamine—Ataxia—Thalidomide—leprosy	0.000472	0.00307	CcSEcCtD
Fluvoxamine—Tachycardia—Dapsone—leprosy	0.000471	0.00306	CcSEcCtD
Fluvoxamine—Dehydration—Thalidomide—leprosy	0.000467	0.00304	CcSEcCtD
Fluvoxamine—Liver function test abnormal—Thalidomide—leprosy	0.000464	0.00302	CcSEcCtD
Fluvoxamine—Dry skin—Thalidomide—leprosy	0.000461	0.00299	CcSEcCtD
Fluvoxamine—Orthostatic hypotension—Thalidomide—leprosy	0.000459	0.00298	CcSEcCtD
Fluvoxamine—Hypokalaemia—Thalidomide—leprosy	0.000457	0.00297	CcSEcCtD
Fluvoxamine—Breast disorder—Thalidomide—leprosy	0.000454	0.00295	CcSEcCtD
Fluvoxamine—Toxic epidermal necrolysis—Thalidomide—leprosy	0.000452	0.00294	CcSEcCtD
Fluvoxamine—Muscular weakness—Thalidomide—leprosy	0.000443	0.00288	CcSEcCtD
Fluvoxamine—Abdominal distension—Thalidomide—leprosy	0.000437	0.00284	CcSEcCtD
Fluvoxamine—Insomnia—Dapsone—leprosy	0.000436	0.00284	CcSEcCtD
Fluvoxamine—Dysphagia—Thalidomide—leprosy	0.000434	0.00282	CcSEcCtD
Fluvoxamine—Influenza—Thalidomide—leprosy	0.000434	0.00282	CcSEcCtD
Fluvoxamine—Pancreatitis—Thalidomide—leprosy	0.000426	0.00277	CcSEcCtD
Fluvoxamine—Angina pectoris—Thalidomide—leprosy	0.000423	0.00275	CcSEcCtD
Fluvoxamine—Bronchitis—Thalidomide—leprosy	0.000418	0.00272	CcSEcCtD
Fluvoxamine—Upper respiratory tract infection—Thalidomide—leprosy	0.000404	0.00262	CcSEcCtD
Fluvoxamine—Pollakiuria—Thalidomide—leprosy	0.000401	0.00261	CcSEcCtD
Fluvoxamine—Erectile dysfunction—Thalidomide—leprosy	0.0004	0.0026	CcSEcCtD
Fluvoxamine—Photosensitivity reaction—Thalidomide—leprosy	0.000396	0.00258	CcSEcCtD
Fluvoxamine—Weight increased—Thalidomide—leprosy	0.000395	0.00257	CcSEcCtD
Fluvoxamine—Gastrointestinal pain—Dapsone—leprosy	0.000395	0.00256	CcSEcCtD
Fluvoxamine—Weight decreased—Thalidomide—leprosy	0.000393	0.00255	CcSEcCtD
Fluvoxamine—Hyperglycaemia—Thalidomide—leprosy	0.000392	0.00255	CcSEcCtD
Fluvoxamine—Pneumonia—Thalidomide—leprosy	0.000389	0.00253	CcSEcCtD
Fluvoxamine—Drowsiness—Thalidomide—leprosy	0.000387	0.00252	CcSEcCtD
Fluvoxamine—Depression—Thalidomide—leprosy	0.000386	0.00251	CcSEcCtD
Fluvoxamine—Stevens-Johnson syndrome—Thalidomide—leprosy	0.000384	0.0025	CcSEcCtD
Fluvoxamine—Acute coronary syndrome—Thalidomide—leprosy	0.000382	0.00248	CcSEcCtD
Fluvoxamine—Body temperature increased—Dapsone—leprosy	0.000381	0.00248	CcSEcCtD
Fluvoxamine—Abdominal pain—Dapsone—leprosy	0.000381	0.00248	CcSEcCtD
Fluvoxamine—Renal failure—Thalidomide—leprosy	0.000381	0.00247	CcSEcCtD
Fluvoxamine—Neuropathy peripheral—Thalidomide—leprosy	0.00038	0.00247	CcSEcCtD
Fluvoxamine—Myocardial infarction—Thalidomide—leprosy	0.00038	0.00247	CcSEcCtD
Fluvoxamine—Stomatitis—Thalidomide—leprosy	0.000377	0.00245	CcSEcCtD
Fluvoxamine—Conjunctivitis—Thalidomide—leprosy	0.000376	0.00245	CcSEcCtD
Fluvoxamine—Sweating—Thalidomide—leprosy	0.000371	0.00241	CcSEcCtD
Fluvoxamine—Haematuria—Thalidomide—leprosy	0.000369	0.0024	CcSEcCtD
Fluvoxamine—Epistaxis—Thalidomide—leprosy	0.000365	0.00237	CcSEcCtD
Fluvoxamine—Sinusitis—Thalidomide—leprosy	0.000363	0.00236	CcSEcCtD
Fluvoxamine—Agranulocytosis—Thalidomide—leprosy	0.000361	0.00235	CcSEcCtD
Fluvoxamine—Bradycardia—Thalidomide—leprosy	0.000354	0.0023	CcSEcCtD
Fluvoxamine—Rhinitis—Thalidomide—leprosy	0.000348	0.00227	CcSEcCtD
Fluvoxamine—Hepatitis—Thalidomide—leprosy	0.000348	0.00226	CcSEcCtD
Fluvoxamine—Hypoaesthesia—Thalidomide—leprosy	0.000346	0.00225	CcSEcCtD
Fluvoxamine—Pharyngitis—Thalidomide—leprosy	0.000345	0.00224	CcSEcCtD
Fluvoxamine—Urinary tract disorder—Thalidomide—leprosy	0.000343	0.00223	CcSEcCtD
Fluvoxamine—Oedema peripheral—Thalidomide—leprosy	0.000342	0.00223	CcSEcCtD
Fluvoxamine—Urethral disorder—Thalidomide—leprosy	0.000341	0.00222	CcSEcCtD
Fluvoxamine—Visual impairment—Thalidomide—leprosy	0.000335	0.00218	CcSEcCtD
Fluvoxamine—Erythema multiforme—Thalidomide—leprosy	0.000329	0.00214	CcSEcCtD
Fluvoxamine—Eye disorder—Thalidomide—leprosy	0.000325	0.00211	CcSEcCtD
Fluvoxamine—Tinnitus—Thalidomide—leprosy	0.000324	0.00211	CcSEcCtD
Fluvoxamine—Cardiac disorder—Thalidomide—leprosy	0.000323	0.0021	CcSEcCtD
Fluvoxamine—Angiopathy—Thalidomide—leprosy	0.000315	0.00205	CcSEcCtD
Fluvoxamine—Chills—Thalidomide—leprosy	0.000312	0.00203	CcSEcCtD
Fluvoxamine—Arrhythmia—Thalidomide—leprosy	0.000311	0.00202	CcSEcCtD
Fluvoxamine—Alopecia—Thalidomide—leprosy	0.000307	0.002	CcSEcCtD
Fluvoxamine—Vomiting—Dapsone—leprosy	0.000307	0.00199	CcSEcCtD
Fluvoxamine—Mental disorder—Thalidomide—leprosy	0.000305	0.00198	CcSEcCtD
Fluvoxamine—Malnutrition—Thalidomide—leprosy	0.000303	0.00197	CcSEcCtD
Fluvoxamine—Headache—Dapsone—leprosy	0.000302	0.00196	CcSEcCtD
Fluvoxamine—Flatulence—Thalidomide—leprosy	0.000298	0.00194	CcSEcCtD
Fluvoxamine—Tension—Thalidomide—leprosy	0.000297	0.00193	CcSEcCtD
Fluvoxamine—Dysgeusia—Thalidomide—leprosy	0.000296	0.00193	CcSEcCtD
Fluvoxamine—Nervousness—Thalidomide—leprosy	0.000294	0.00191	CcSEcCtD
Fluvoxamine—Back pain—Thalidomide—leprosy	0.000293	0.0019	CcSEcCtD
Fluvoxamine—Muscle spasms—Thalidomide—leprosy	0.000291	0.00189	CcSEcCtD
Fluvoxamine—Nausea—Dapsone—leprosy	0.000287	0.00186	CcSEcCtD
Fluvoxamine—Vision blurred—Thalidomide—leprosy	0.000285	0.00185	CcSEcCtD
Fluvoxamine—Tremor—Thalidomide—leprosy	0.000284	0.00184	CcSEcCtD
Fluvoxamine—Ill-defined disorder—Thalidomide—leprosy	0.000281	0.00183	CcSEcCtD
Fluvoxamine—Anaemia—Thalidomide—leprosy	0.00028	0.00182	CcSEcCtD
Fluvoxamine—Agitation—Thalidomide—leprosy	0.000278	0.00181	CcSEcCtD
Fluvoxamine—Angioedema—Thalidomide—leprosy	0.000277	0.0018	CcSEcCtD
Fluvoxamine—Malaise—Thalidomide—leprosy	0.000273	0.00177	CcSEcCtD
Fluvoxamine—Vertigo—Thalidomide—leprosy	0.000272	0.00177	CcSEcCtD
Fluvoxamine—Syncope—Thalidomide—leprosy	0.000271	0.00176	CcSEcCtD
Fluvoxamine—Leukopenia—Thalidomide—leprosy	0.000271	0.00176	CcSEcCtD
Fluvoxamine—Palpitations—Thalidomide—leprosy	0.000267	0.00174	CcSEcCtD
Fluvoxamine—Loss of consciousness—Thalidomide—leprosy	0.000266	0.00173	CcSEcCtD
Fluvoxamine—Cough—Thalidomide—leprosy	0.000264	0.00172	CcSEcCtD
Fluvoxamine—Convulsion—Thalidomide—leprosy	0.000262	0.0017	CcSEcCtD
Fluvoxamine—Hypertension—Thalidomide—leprosy	0.000261	0.0017	CcSEcCtD
Fluvoxamine—Chest pain—Thalidomide—leprosy	0.000258	0.00167	CcSEcCtD
Fluvoxamine—Myalgia—Thalidomide—leprosy	0.000258	0.00167	CcSEcCtD
Fluvoxamine—Arthralgia—Thalidomide—leprosy	0.000258	0.00167	CcSEcCtD
Fluvoxamine—Anxiety—Thalidomide—leprosy	0.000257	0.00167	CcSEcCtD
Fluvoxamine—Discomfort—Thalidomide—leprosy	0.000255	0.00165	CcSEcCtD
Fluvoxamine—Dry mouth—Thalidomide—leprosy	0.000252	0.00164	CcSEcCtD
Fluvoxamine—Confusional state—Thalidomide—leprosy	0.000249	0.00162	CcSEcCtD
Fluvoxamine—Oedema—Thalidomide—leprosy	0.000247	0.00161	CcSEcCtD
Fluvoxamine—Infection—Thalidomide—leprosy	0.000245	0.00159	CcSEcCtD
Fluvoxamine—Shock—Thalidomide—leprosy	0.000243	0.00158	CcSEcCtD
Fluvoxamine—Nervous system disorder—Thalidomide—leprosy	0.000242	0.00157	CcSEcCtD
Fluvoxamine—Thrombocytopenia—Thalidomide—leprosy	0.000242	0.00157	CcSEcCtD
Fluvoxamine—Tachycardia—Thalidomide—leprosy	0.000241	0.00157	CcSEcCtD
Fluvoxamine—Hyperhidrosis—Thalidomide—leprosy	0.000239	0.00155	CcSEcCtD
Fluvoxamine—Anorexia—Thalidomide—leprosy	0.000235	0.00153	CcSEcCtD
Fluvoxamine—Hypotension—Thalidomide—leprosy	0.000231	0.0015	CcSEcCtD
Fluvoxamine—Musculoskeletal discomfort—Thalidomide—leprosy	0.000225	0.00146	CcSEcCtD
Fluvoxamine—Insomnia—Thalidomide—leprosy	0.000223	0.00145	CcSEcCtD
Fluvoxamine—Paraesthesia—Thalidomide—leprosy	0.000222	0.00144	CcSEcCtD
Fluvoxamine—Dyspnoea—Thalidomide—leprosy	0.00022	0.00143	CcSEcCtD
Fluvoxamine—Somnolence—Thalidomide—leprosy	0.00022	0.00143	CcSEcCtD
Fluvoxamine—Dyspepsia—Thalidomide—leprosy	0.000217	0.00141	CcSEcCtD
Fluvoxamine—Decreased appetite—Thalidomide—leprosy	0.000215	0.0014	CcSEcCtD
Fluvoxamine—Gastrointestinal disorder—Thalidomide—leprosy	0.000213	0.00139	CcSEcCtD
Fluvoxamine—Fatigue—Thalidomide—leprosy	0.000213	0.00138	CcSEcCtD
Fluvoxamine—Pain—Thalidomide—leprosy	0.000211	0.00137	CcSEcCtD
Fluvoxamine—Constipation—Thalidomide—leprosy	0.000211	0.00137	CcSEcCtD
Fluvoxamine—Feeling abnormal—Thalidomide—leprosy	0.000204	0.00132	CcSEcCtD
Fluvoxamine—Gastrointestinal pain—Thalidomide—leprosy	0.000202	0.00131	CcSEcCtD
Fluvoxamine—Urticaria—Thalidomide—leprosy	0.000196	0.00128	CcSEcCtD
Fluvoxamine—Abdominal pain—Thalidomide—leprosy	0.000195	0.00127	CcSEcCtD
Fluvoxamine—Body temperature increased—Thalidomide—leprosy	0.000195	0.00127	CcSEcCtD
Fluvoxamine—Hypersensitivity—Thalidomide—leprosy	0.000182	0.00118	CcSEcCtD
Fluvoxamine—Asthenia—Thalidomide—leprosy	0.000177	0.00115	CcSEcCtD
Fluvoxamine—Pruritus—Thalidomide—leprosy	0.000175	0.00114	CcSEcCtD
Fluvoxamine—Diarrhoea—Thalidomide—leprosy	0.000169	0.0011	CcSEcCtD
Fluvoxamine—Dizziness—Thalidomide—leprosy	0.000163	0.00106	CcSEcCtD
Fluvoxamine—Vomiting—Thalidomide—leprosy	0.000157	0.00102	CcSEcCtD
Fluvoxamine—Rash—Thalidomide—leprosy	0.000156	0.00101	CcSEcCtD
Fluvoxamine—Dermatitis—Thalidomide—leprosy	0.000156	0.00101	CcSEcCtD
Fluvoxamine—Headache—Thalidomide—leprosy	0.000155	0.00101	CcSEcCtD
Fluvoxamine—Nausea—Thalidomide—leprosy	0.000147	0.000954	CcSEcCtD
